| P2093 | author name string | Renate Arnold | |
| | Theo D Kim | |
| | Theis H Terwey | |
| P2860 | cites work | Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials | Q30997153 |
| | Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials | Q31064796 |
| | Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival | Q33816659 |
| | High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation | Q34582448 |
| | Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia | Q35750934 |
| | Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission | Q36742516 |
| | Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. | Q37051052 |
| | The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation | Q37143670 |
| | Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). | Q38384261 |
| | Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study | Q43889424 |
| | Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study | Q44047915 |
| | Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia | Q44073599 |
| | Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease | Q44231547 |
| | Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation | Q44250679 |
| | Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy | Q44258556 |
| | The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia | Q44318362 |
| | Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia | Q44499780 |
| | Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate | Q44612967 |
| | Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients | Q44843030 | |
| | Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission | Q44978580 |
| | Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial | Q44980750 |
| | Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission | Q45267630 |
| | Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. | Q45309204 |
| | Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. | Q46140796 |
| | Treatment of adult acute lymphoblastic leukemia | Q46187922 |
| | Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). | Q46427718 |
| | Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study | Q46529375 |
| | In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid | Q47596252 |
| | A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission | Q47603523 |
| | Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transp | Q53010889 |
| | Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. | Q54639337 |
| | Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia | Q57918815 |
| | Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) | Q58414406 |
| | Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia | Q58865943 |
| | T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse | Q61651705 |
| | A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation | Q66829333 |
| | Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia | Q72880106 |
| | Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow | Q73089048 |
| | Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study | Q73390033 |
| | The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia | Q74459338 |
| | Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation | Q77647316 |
| | Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia | Q78680158 |
| | Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison | Q79802931 |
| | The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products | Q80210108 |
| | Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia | Q80292597 |
| | A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation | Q80493822 |
| | Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial | Q80537988 |
| | Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial | Q80568663 |
| | Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation | Q80620917 |
| | Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study | Q81309439 |
| | Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial | Q81340587 |
| P433 | issue | 3 | |
| P921 | main subject | leukemia | Q29496 |
| | lymphocyte | Q715347 |
| | stem cell transplantation | Q65592366 |
| P304 | page(s) | 139-147 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | Current hematologic malignancy reports | Q26842233 |
| P1476 | title | Allogeneic hematopoietic stem cell transplantation for adult acute lymphocytic leukemia | |
| P478 | volume | 4 | |